Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Bone. 2018 Sep 3;117:37–46. doi: 10.1016/j.bone.2018.08.025

Figure 3. Pharmacological inhibition of PRMT5 resulted in STAT1 downmodulation and differential blockade of histone symmetric dimethyl arginine modifications in mesenchymal stromal cells, ST-2 and W-20.

Figure 3.

Inhibition of methyl transferase activity of PRMT5 (using GSK3235025) led to a downmodulation of STAT1 protein levels but not the levels of PRMT5 (A: western blot and B: protein band density quantitation). Decrease in global levels of symmetric dimethyl arginine marks on H4R3me2s and H3R8me2s but not H3R2me2s as assessed by western blot (C) as well as immunofluorescence (D) analyses. P5i: PRMT5 inhibitor (0.625 uM and 1.25 uM). *indicates non-specific band.